Management of Hematuria in NSTEMI Patients on Heparin

Introduction to Hematuria Management

The American College of Cardiology/American Heart Association (ACC/AHA) guidelines recommend immediate evaluation and adjustment of therapy in patients who develop clinically significant bleeding during heparin therapy, including hematuria 1, 2
Hematuria in a patient on heparin represents a significant change in the patient's clinical condition that warrants immediate attention, according to the ACC/AHA guidelines 1, 2

When hematuria develops in a patient on heparin, immediately check complete blood count, coagulation parameters (aPTT), hemodynamic stability, and urinalysis to quantify the degree of hematuria 1, 2
Evaluate for underlying urological pathology, as research suggests that up to 59% of patients on anticoagulants who develop hematuria have significant underlying urological conditions, although the specific percentage is not cited in this context

Fondaparinux may be considered as an alternative anticoagulant if renal function is adequate (CrCl >30 mL/min), with a lower bleeding risk compared to low molecular weight heparin (LMWH) in NSTEMI patients 3
Bivalirudin may be considered as an alternative to unfractionated heparin (UFH), with a lower bleeding risk and no renal dosing required for moderate renal impairment 3, 4

Serial hemoglobin/hematocrit measurements should be taken to ensure stabilization after hematuria develops 1, 2
Monitor urine output and color to assess resolution of hematuria
If anticoagulation must be resumed after hematuria resolves, consider a different anticoagulant with potentially lower bleeding risk, use lower doses with careful monitoring, and avoid crossover between different anticoagulants (e.g., UFH and LMWH) as this increases bleeding risk 3

The ACC/AHA guidelines suggest that early discontinuation of heparin may be reasonable if bleeding occurs, as the optimal duration of therapy remains undefined 1
Balancing thrombotic and bleeding risks is crucial, and active bleeding represents a clear indication to reassess the risk-benefit ratio
Continuing anticoagulation despite active bleeding can lead to worsening hemorrhage and hemodynamic compromise, and the presence of hematuria should not be dismissed as a minor complication 1, 2